Immunology : Impact Factor & More
eISSN: 1365-2567pISSN: 0019-2805
Share this on:
Key Metrics
CiteScore 
13.4
H-Index
149
Impact Factor
5 - 10
SJR
Q1Immunology
SNIP
1.65
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Immunology
Immunology Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1958 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Immunology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Immunology
R-5780, a SagA-engineered Lactococcus lactis, is a safe oral synthetic-biology microbial therapy that potentiates PD-1 blockade.
- 30 Jun 2026
- Cancer immunology, immunotherapy : CII
Downregulation of ANKRD22 promotes ovarian cancer cell proliferation by enhancing the immunosuppressive capacity of M-MDSCs.
- 30 Jun 2026
- Cancer immunology, immunotherapy : CII
The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
CD68+ tumor-associated macrophages exhibit prognostic value in surgically resected small cell lung cancer: a retrospective cohort study of 614 patients.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
Timing of immune checkpoint inhibitors infusion and prognosis in recurrent/metastatic nasopharyngeal carcinoma: a single-center, retrospective study.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
- 23 Jun 2026
- Cancer immunology, immunotherapy : CII
R-5780, a SagA-engineered Lactococcus lactis, is a safe oral synthetic-biology microbial therapy that potentiates PD-1 blockade.
- 30 Jun 2026
- Cancer immunology, immunotherapy : CII
Downregulation of ANKRD22 promotes ovarian cancer cell proliferation by enhancing the immunosuppressive capacity of M-MDSCs.
- 30 Jun 2026
- Cancer immunology, immunotherapy : CII
The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
CD68+ tumor-associated macrophages exhibit prognostic value in surgically resected small cell lung cancer: a retrospective cohort study of 614 patients.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
Timing of immune checkpoint inhibitors infusion and prognosis in recurrent/metastatic nasopharyngeal carcinoma: a single-center, retrospective study.
- 29 Jun 2026
- Cancer immunology, immunotherapy : CII
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
- 23 Jun 2026
- Cancer immunology, immunotherapy : CII
FAQs on Immunology
How long has Immunology been actively publishing? 
What is the publishing frequency of Immunology?
How many articles did Immunology publish last year?
What is the eISSN & pISSN for Immunology?
What is Citescore for Immunology?
What is the H Index for Immunology ?
What is SNIP score for Immunology?
What is the SJR for Immunology?
Who is the publisher of Immunology?
